Cargando…

Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand?

Allogeneic hematopoietic stem cell transplantation (HSCT) is an established curative treatment that has significantly improved clinical outcome of pediatric patients with malignant and non-malignant disorders. This is partly because of the use of safer and more effective combinations of chemo- and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Stoep, M. Y. Eileen C., Oostenbrink, Lisa V. E., Bredius, Robbert G. M., Moes, Dirk Jan A. R., Guchelaar, Henk-Jan, Zwaveling, Juliette, Lankester, Arjan C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940165/ https://www.ncbi.nlm.nih.gov/pubmed/35330826 http://dx.doi.org/10.3389/fphar.2022.826004

Ejemplares similares

Treosulfan-induced myalgia in pediatric hematopoietic stem cell transplantation identified by an electronic health record text mining tool
por: van der Stoep, M. Y. Eileen C., et al.
Publicado: (2021)

Phytotherapy for Cachexia: Where Do We Stand?
por: Kuchta, Kenny, et al.
Publicado: (2020)

Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation
por: van der Stoep, M. Y. E. C., et al.
Publicado: (2019)

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study
por: Achini-Gutzwiller, Federica R., et al.
Publicado: (2023)

Neutrino Masses and Mixing: Where We Stand and Where We are Going
por: Gonzalez-Garcia, M.C.
Publicado: (2002)

FKBP Ligands—Where We Are and Where to Go?
por: Kolos, Jürgen M., et al.
Publicado: (2018)

Where Do We Stand?
Publicado: (1891)

Cancer: Where We Stand
Publicado: (1951)

Complete Suppression of the Gut Microbiome Prevents Acute Graft-Versus-Host Disease following Allogeneic Bone Marrow Transplantation
por: Vossen, Jaak M., et al.
Publicado: (2014)

An Electronic Health Record Text Mining Tool to Collect Real‐World Drug Treatment Outcomes: A Validation Study in Patients With Metastatic Renal Cell Carcinoma
por: van Laar, Sylvia A., et al.
Publicado: (2020)

Where do we stand with IPF treatment?
por: Albera, C, et al.
Publicado: (2013)

Joint Discussion – Where we stand and where we want to go
por: CERN. Geneva
Publicado: (2013)

Joint Discussion – Where we stand and where we want to go
por: CERN. Geneva
Publicado: (2013)

Alzheimer’s disease and infections, where we stand and where we go
por: Monastero, Roberto, et al.
Publicado: (2014)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

Assessment of Liver Function With MRI: Where Do We Stand?
por: Río Bártulos, Carolina, et al.
Publicado: (2022)

New Trends in Injection-Based Therapy for Thumb-Base Osteoarthritis: Where Are We and where Are We Going?
por: Tenti, Sara, et al.
Publicado: (2021)

CHRONIC AUTOIMMUNE URTICARIA: WHERE WE STAND?
por: Goh, C L, et al.
Publicado: (2009)

Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand
por: Lazana, Ioanna
Publicado: (2023)

Scoping review of brucellosis in Cameroon: Where do we stand, and where are we going?
por: Laine, Christopher G., et al.
Publicado: (2020)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Where we stand with the real superworld
por: Zichichi, Antonino
Publicado: (1993)

Correcting LEP: where we stand
por: Kleiss, R H
Publicado: (1989)

Recurrent Glioblastoma: Where we stand
por: Roy, Sanjoy, et al.
Publicado: (2015)

Corneal xenotransplantation: Where are we standing?
por: Yoon, Chang Ho, et al.
Publicado: (2021)

Development and Validation of an Efficient and Highly Sensitive Enzyme-Linked Immunosorbent Assay for Alemtuzumab Quantification in Human Serum and Plasma
por: Achini-Gutzwiller, Federica R., et al.
Publicado: (2023)

THREE-DIMENSIONAL PRINTING IN ORTHOPEDICS: WHERE WE STAND AND WHERE WE ARE HEADING
por: EJNISMAN, LEANDRO, et al.
Publicado: (2021)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Sympathetic Modulation in Cardiac Arrhythmias: Where We Stand and Where We Go
por: Chung, Wei-Hsin, et al.
Publicado: (2023)

Application of Electronic Health Record Text Mining: Real-World Tolerability, Safety, and Efficacy of Adjuvant Melanoma Treatments
por: van Laar, Sylvia A., et al.
Publicado: (2022)

Photodynamic therapy of lung cancer, where are we?
por: Crous, Anine, et al.
Publicado: (2022)

Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG Guidelines
por: Manson, Lisanne E. N., et al.
Publicado: (2020)

Genotyping for HLA risk alleles versus patch tests to diagnose anti-seizure medication induced cutaneous adverse drug reactions
por: Manson, Lisanne E. N., et al.
Publicado: (2022)

COVID-19 in Children: Where do we Stand?
por: Nikolopoulou, Georgia B., et al.
Publicado: (2022)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?
por: Agapidou, Alexandra, et al.
Publicado: (2016)

Application of molecular SERS nanosensors: where we stand and where we are headed towards?
por: Jahn, Izabella J., et al.
Publicado: (2020)

Late Sodium Current of the Heart: Where Do We Stand and Where Are We Going?
por: Horváth, Balázs, et al.
Publicado: (2022)

Pediatric urologic oncology in the 21(st) century: where we stand and where we’re headed
por: Routh, Jonathan C., et al.
Publicado: (2020)

Pixel Detectors ... where do we stand?
por: Wermes, Norbert
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nmdnrja9pvct4c37u1vvvsm2nh